Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 74 of 1,261
  1. US 12171864

    Biological self-assembled nanocrystal injection having a lymphatic targeting function and preparation method

    SHENZHEN CHINA RESOURCES JIUCHUANG MEDICAL AND PHARMACEUTICAL CO., LTD Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  2. US 12172994

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  3. US 12171803

    Methods of CD40 and toll like receptor immune activation

    The Board of Regents of the University of Texas System Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  4. US 12171760

    Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

    Corcept Therapeutics Incorporated Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  5. US 12174192

    Methods for detecting and treating cancers having adenosine pathway activation

    Corvus Pharmaceuticals, Inc. Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  6. US 12173306

    Codon-optimized reduced-size ATP7A CDNA and uses for treatment of copper transport disorders

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  7. US 12174205

    Phosphatidylethanolamine-specific probes

    Northwestern University Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  8. US 12173317

    Use of histone modifiers to reprogram effector T cells

    The Board of Regents of the University of Texas System Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  9. US 12173314

    Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

    United States Government as represented by the Department of Veterans Affairs Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  10. US 12173324

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  11. US 12173088

    Anti-microbial peptides

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  12. US 12173274

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  13. US 12173307

    Methods for the purification of viral vectors

    BIOVERATIV THERAPEUTICS INC. Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  14. US 12173087

    Melanocortin 1 receptor ligands and methods of use

    Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  15. US 12173062

    Modified TNF-Ξ± antibodies and uses thereof

    Bright Peak Therapeutics AG Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  16. US 12173069

    Antibodies binding to vista at acidic pH

    Five Prime Therapeutics, Inc. Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  17. US 12173058

    Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

    Mereo Biopharma 3 Limited Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  18. US 12173061

    Compositions and methods for treatment of chronic lung diseases

    The Board of Regents of the University of Texas System Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  19. US 12172038

    Anti-coronavirus antibodies and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Svcs. Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  20. US 12171884

    Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery

    The Regents of the University of California Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  21. US 12172969

    Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof

    EVOFEM BIOSCIENCES, INC. Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  22. US 12173078

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  23. US 12173029

    Antiviral prodrugs, pharmaceutical formulations, and methods

    The Regents of the University of California Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted
  24. US 12173084

    Phosphorylated dicer antibody and methods of use thereof

    The Board of Regents of the University of Texas System Β· Granted Dec 24, 2024 Β· Expires Dec 19, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.